Hualan Biological Vaccine Inc.

SZSE:301207 Stock Report

Market Cap: CN¥12.0b

Hualan Biological Vaccine Valuation

Is 301207 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301207 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301207 (CN¥20.19) is trading below our estimate of fair value (CN¥20.82)

Significantly Below Fair Value: 301207 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301207?

Key metric: As 301207 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 301207. This is calculated by dividing 301207's market cap by their current earnings.
What is 301207's PE Ratio?
PE Ratio24.1x
EarningsCN¥497.61m
Market CapCN¥12.01b

Price to Earnings Ratio vs Peers

How does 301207's PE Ratio compare to its peers?

The above table shows the PE ratio for 301207 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average81.2x
688739 Liaoning Chengda BiotechnologyLtd
34xn/aCN¥11.3b
002675 Yantai Dongcheng Pharmaceutical GroupLtd
120.8x45.9%CN¥11.0b
600645 Vcanbio Cell & Gene Engineering
87.3x23.0%CN¥9.4b
300294 China Resources Boya Bio-pharmaceutical GroupLtd
82.6x44.4%CN¥15.4b
301207 Hualan Biological Vaccine
24.1x33.3%CN¥12.0b

Price-To-Earnings vs Peers: 301207 is good value based on its Price-To-Earnings Ratio (24.1x) compared to the peer average (81.2x).

Price to Earnings Ratio vs Industry

How does 301207's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
301207 24.1xIndustry Avg. 36.6xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 301207 is good value based on its Price-To-Earnings Ratio (24.1x) compared to the CN Biotechs industry average (36.4x).

Price to Earnings Ratio vs Fair Ratio

What is 301207's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301207 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.1x
Fair PE Ratio33.2x

Price-To-Earnings vs Fair Ratio: 301207 is good value based on its Price-To-Earnings Ratio (24.1x) compared to the estimated Fair Price-To-Earnings Ratio (33.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 301207 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥20.19
CN¥27.18
+34.6%
11.1%CN¥30.00CN¥23.00n/a3
Nov ’25CN¥18.67
CN¥27.18
+45.6%
11.1%CN¥30.00CN¥23.00n/a3
Oct ’25CN¥20.78
CN¥27.18
+30.8%
11.1%CN¥30.00CN¥23.00n/a3
Sep ’25CN¥18.33
CN¥29.28
+59.7%
2.5%CN¥30.00CN¥28.55n/a2
Aug ’25CN¥17.29
CN¥29.30
+69.5%
2.4%CN¥30.00CN¥28.60n/a2
Jul ’25CN¥17.39
CN¥29.30
+68.5%
2.4%CN¥30.00CN¥28.60n/a2
Jun ’25CN¥18.82
CN¥29.30
+55.7%
2.4%CN¥30.00CN¥28.60n/a2
May ’25CN¥21.98
CN¥33.20
+51.0%
16.7%CN¥41.00CN¥28.60n/a3
Apr ’25CN¥24.33
CN¥33.20
+36.5%
16.7%CN¥41.00CN¥28.60n/a3
Mar ’25CN¥24.78
CN¥37.89
+52.9%
6.5%CN¥41.00CN¥35.00n/a3
Feb ’25CN¥21.97
CN¥37.89
+72.5%
6.5%CN¥41.00CN¥35.00n/a3
Jan ’25CN¥27.80
CN¥37.89
+36.3%
6.5%CN¥41.00CN¥35.00n/a3
Dec ’24CN¥31.68
CN¥37.89
+19.6%
6.5%CN¥41.00CN¥35.00n/a3
Nov ’24CN¥29.70
CN¥37.89
+27.6%
6.5%CN¥41.00CN¥35.00CN¥18.673

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.21

7D

-3.1%

1Y

17.4%

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥29.94

7D

-9.9%

1Y

7.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.72

7D

-1.2%

1Y

18.8%